For more than 80 years, men have been told that testosterone helps prostate cancer grow. But a very different picture has emerged over the past two decades.

SAN FRANCISCO—Testosterone replacement therapy (TRT) for men with a history of prostate cancer (PCa) does not increase recurrence rates following radical treatment or progression rate after placement ...

The testosterone threshold should be less than 10 ng/dL rather than less than 50 ng/dL for gauging advanced prostate cancer prognosis in patients on ADT. Examining sustained testosterone suppression ...

Testosterone recovery post-ADT is influenced by treatment duration, baseline testosterone levels, and patient age. Younger patients and those with higher baseline testosterone levels recover more ...

Compared to other treatments, patients’ testosterone levels return to baseline levels faster following treatment with Orgovyx. Among patients with prostate cancer, treatment with the oral ...

Although the Endocrine Society guidelines recommend TRT for men with testosterone levels ≤ 300 ng/dL in two morning samples, a primary concern is its potential to exacerbate prostate-related ...

SAN ANTONIO — A small pilot study delivered a big message about the use of testosterone in men with advanced or metastatic prostate cancer, according to a "Best Abstract" presented at the Sexual ...

Combining testosterone-blocking drugs in patients with prostate cancer relapse prevents the spread of cancer better than treatment with a single drug, a multi-institution, phase 3 clinical trial led ...

This article was reviewed by Darragh O’Carroll, MD. PSA and Testosterone: Are They Linked? Prostate-specific antigen (PSA) is a term you’ll probably become familiar with once you start getting ...

Testosterone testing and treatment have increased significantly over the past 2 decades, yet clinical practices remain inconsistent. 1,2 Despite rising awareness and prescription trends, up to 25% of ...

If you have prostate cancer, your health care provider may have told you about a medicine called Nubeqa (darolutamide). The FDA approved Nubeqa in 2019. It is commonly used to treat prostate cancer ...